ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1215

Development of a Multivariable Prediction Model for Treatment Response to Etanercept in a Multi-centre Cohort of Patients with Established RA
Abstract Number: 0063

Development of a Novel Cartilage Model Co-cultured with Conditioned Medium from Th17 Cells to Explore the Effect of IL-17A on Joint Tissue Remodeling
Abstract Number: 1576

Development of a Plain Radiographic Scoring System for New Bone Formation in Gout
Abstract Number: 0532

Development of a Predictive Tool for the Rapid Progressive Knee Osteoarthritis Phenotype: Data from the Osteoarthritis Initiative
Abstract Number: 0761

Development of a Symptom Diary for Use in Patients with Sjogren’s Syndrome
Abstract Number: 1526

Development of Antinuclear Antibodies and Systemic Lupus Erythematosus in Patients on Tumor Necrosis Factor α Inhibitor Therapy
Abstract Number: 0524

Development of Biomarker Models to Identify HLA-related Microbiome Associations in Anti-Ro+ Mothers of Children with Neonatal Lupus
Abstract Number: 0244

Development of Candidate Criteria for Axial Disease in Juvenile Spondyloarthritis: An International Collaboration
Abstract Number: 0149

Development of Joint Effusion, Hyperperfusion and Enthesitis After One Hour of Age-and Gender Adjusted Weight Training
Abstract Number: 0676

Development, Refinement, and Validation of an Emergency Department Gout Flare Electronic Medical Record Alert
Abstract Number: 0163

Diagnosis of Giant Cell Arteritis in Spain: Data from the ARTESER Registry
Abstract Number: 0826

Diagnosis, Treatment and Utilization Changes in Rheumatoid Arthritis Patients Before and During COVID-19
Abstract Number: 1582

Diagnostic Accuracy and Reliability of Conventional Radiography of the Knee in Calcium Pyrophosphate Deposition Disease by Using New Definitions: An Ancillary Study of the OMERACT Ultrasound – CPPD Group
Abstract Number: 0714

Diagnostic Accuracy of Electromyogram for Myositis
Abstract Number: 0425

Diagnostic Accuracy of Muscle MRI for Muscular Vasculitis in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis: A Pilot Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].